Kane Biotech Inc. (KNBIF)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -3.35 Million CAD | 0.19% |
| 2022 | -3.36 Million CAD | 31.12% |
| 2021 | -4.88 Million CAD | -15.6% |
| 2020 | -4.22 Million CAD | -17.66% |
| 2019 | -3.59 Million CAD | -12.94% |
| 2018 | -3.17 Million CAD | -17.95% |
| 2017 | -2.69 Million CAD | -10.7% |
| 2016 | -2.43 Million CAD | -50.99% |
| 2015 | -1.61 Million CAD | -5.87% |
| 2014 | -1.52 Million CAD | -4.99% |
| 2013 | -1.45 Million CAD | 0.91% |
| 2012 | -1.46 Million CAD | -18.51% |
| 2011 | -1.23 Million CAD | -26.06% |
| 2010 | -979.92 Thousand CAD | -10.86% |
| 2009 | -883.89 Thousand CAD | 11.35% |
| 2008 | -997.05 Thousand CAD | 3.68% |
| 2007 | -1.03 Million CAD | -19.19% |
| 2006 | -868.48 Thousand CAD | 16.1% |
| 2005 | -1.03 Million CAD | -71.79% |
| 2004 | -602.56 Thousand CAD | -48.58% |
| 2003 | -405.54 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -1.23 Million CAD | -65.55% |
| 2024 Q2 | -1.1 Million CAD | 10.4% |
| 2023 FY | -3.82 Million CAD | -13.65% |
| 2023 Q3 | -1.19 Million CAD | -123.6% |
| 2023 Q1 | -1.01 Million CAD | -83.47% |
| 2023 Q2 | -535.72 Thousand CAD | 47.26% |
| 2023 Q4 | -743.49 Thousand CAD | 37.93% |
| 2022 Q2 | -722.09 Thousand CAD | 41.6% |
| 2022 Q4 | -553.64 Thousand CAD | 34.99% |
| 2022 FY | -3.36 Million CAD | 31.12% |
| 2022 Q1 | -1.23 Million CAD | 5.13% |
| 2022 Q3 | -851.59 Thousand CAD | -17.93% |
| 2021 Q2 | -1 Million CAD | -2.35% |
| 2021 Q1 | -983.73 Thousand CAD | 7.7% |
| 2021 FY | -4.88 Million CAD | -15.6% |
| 2021 Q3 | -1.58 Million CAD | -57.89% |
| 2021 Q4 | -1.3 Million CAD | 18.01% |
| 2020 Q2 | -595.87 Thousand CAD | 58.76% |
| 2020 Q1 | -1.44 Million CAD | -18.26% |
| 2020 Q4 | -1.06 Million CAD | 4.67% |
| 2020 FY | -4.22 Million CAD | -17.66% |
| 2020 Q3 | -1.11 Million CAD | -87.62% |
| 2019 Q2 | -953.47 Thousand CAD | -53.97% |
| 2019 Q4 | -1.22 Million CAD | -53.53% |
| 2019 FY | -3.59 Million CAD | -12.94% |
| 2019 Q3 | -795.73 Thousand CAD | 16.54% |
| 2019 Q1 | -619.27 Thousand CAD | 6.52% |
| 2018 Q4 | -662.47 Thousand CAD | 28.55% |
| 2018 Q2 | -700.06 Thousand CAD | 21.26% |
| 2018 FY | -3.17 Million CAD | -17.95% |
| 2018 Q3 | -927.23 Thousand CAD | -32.45% |
| 2018 Q1 | -889.06 Thousand CAD | -0.07% |
| 2017 Q4 | -888.43 Thousand CAD | -2.83% |
| 2017 Q3 | -863.98 Thousand CAD | -18.12% |
| 2017 Q2 | -731.41 Thousand CAD | -246.45% |
| 2017 FY | -2.69 Million CAD | -10.7% |
| 2017 Q1 | -211.12 Thousand CAD | 55.68% |
| 2016 Q4 | -476.37 Thousand CAD | 20.28% |
| 2016 Q1 | -529.3 Thousand CAD | -15.92% |
| 2016 FY | -2.43 Million CAD | -50.99% |
| 2016 Q3 | -597.52 Thousand CAD | 28.12% |
| 2016 Q2 | -831.31 Thousand CAD | -57.06% |
| 2015 Q3 | -383.49 Thousand CAD | -24.18% |
| 2015 Q4 | -456.61 Thousand CAD | -19.07% |
| 2015 FY | -1.61 Million CAD | -5.87% |
| 2015 Q2 | -308.83 Thousand CAD | 33.36% |
| 2015 Q1 | -463.43 Thousand CAD | -8.3% |
| 2014 Q1 | -288.5 Thousand CAD | -140.09% |
| 2014 Q2 | -489.13 Thousand CAD | -69.54% |
| 2014 Q3 | -317.44 Thousand CAD | 35.1% |
| 2014 FY | -1.52 Million CAD | -4.99% |
| 2014 Q4 | -427.9 Thousand CAD | -34.8% |
| 2013 Q3 | -331.27 Thousand CAD | -0.52% |
| 2013 Q2 | -329.55 Thousand CAD | 50.79% |
| 2013 FY | -1.45 Million CAD | 0.91% |
| 2013 Q1 | -669.62 Thousand CAD | -62.5% |
| 2013 Q4 | -120.16 Thousand CAD | 63.73% |
| 2012 Q2 | -350.18 Thousand CAD | -13.09% |
| 2012 Q3 | -391.98 Thousand CAD | -11.93% |
| 2012 Q4 | -412.06 Thousand CAD | -5.12% |
| 2012 FY | -1.46 Million CAD | -18.51% |
| 2012 Q1 | -309.66 Thousand CAD | -2.33% |
| 2011 Q4 | -302.6 Thousand CAD | 13.34% |
| 2011 Q3 | -349.19 Thousand CAD | -52.68% |
| 2011 FY | -1.23 Million CAD | -26.06% |
| 2011 Q2 | -228.71 Thousand CAD | 35.53% |
| 2011 Q1 | -354.73 Thousand CAD | -79.79% |
| 2010 Q3 | -264.23 Thousand CAD | -43.35% |
| 2010 Q4 | -197.3 Thousand CAD | 25.33% |
| 2010 FY | -979.92 Thousand CAD | -10.86% |
| 2010 Q1 | -280.06 Thousand CAD | -163.18% |
| 2010 Q2 | -184.33 Thousand CAD | 34.18% |
| 2009 Q4 | -106.41 Thousand CAD | 65.51% |
| 2009 FY | -883.89 Thousand CAD | 11.35% |
| 2009 Q1 | -206.09 Thousand CAD | -75.44% |
| 2009 Q3 | -308.56 Thousand CAD | -30.89% |
| 2009 Q2 | -235.74 Thousand CAD | -14.39% |
| 2008 FY | -997.05 Thousand CAD | 3.68% |
| 2008 Q4 | -117.46 Thousand CAD | 68.51% |
| 2008 Q2 | -352.17 Thousand CAD | -65.68% |
| 2008 Q1 | -212.55 Thousand CAD | 25.67% |
| 2008 Q3 | -372.99 Thousand CAD | -5.91% |
| 2007 Q2 | -382.3 Thousand CAD | -96.61% |
| 2007 Q4 | -285.96 Thousand CAD | -65.99% |
| 2007 Q3 | -172.27 Thousand CAD | 54.94% |
| 2007 FY | -1.03 Million CAD | -19.19% |
| 2007 Q1 | -194.44 Thousand CAD | 27.06% |
| 2006 Q1 | -159.95 Thousand CAD | 44.05% |
| 2006 FY | -868.48 Thousand CAD | 16.1% |
| 2006 Q3 | -201.93 Thousand CAD | 16.87% |
| 2006 Q2 | -242.91 Thousand CAD | -51.86% |
| 2006 Q4 | -266.6 Thousand CAD | -32.03% |
| 2005 Q2 | -270.93 Thousand CAD | -29.06% |
| 2005 Q4 | -285.87 Thousand CAD | -10.15% |
| 2005 FY | -1.03 Million CAD | -71.79% |
| 2005 Q1 | -209.93 Thousand CAD | 11.57% |
| 2005 Q3 | -259.52 Thousand CAD | 4.21% |
| 2004 Q1 | -107.03 Thousand CAD | -111.74% |
| 2004 FY | -602.56 Thousand CAD | -48.58% |
| 2004 Q3 | -99.16 Thousand CAD | 33.2% |
| 2004 Q2 | -148.46 Thousand CAD | -38.7% |
| 2004 Q4 | -237.39 Thousand CAD | -139.4% |
| 2003 Q4 | -50.54 Thousand CAD | 71.09% |
| 2003 FY | -405.54 Thousand CAD | 0.0% |
| 2003 Q2 | -24.18 Thousand CAD | 0.0% |
| 2003 Q3 | -174.86 Thousand CAD | -623.02% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -3.16 Million USD | -5.969% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -260.474% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -27.778% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 81.188% |
| GB Sciences, Inc. | -1.42 Million USD | -136.351% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 1.398% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -1425.544% |
| Skye Bioscience, Inc. | -13.67 Million USD | 75.443% |
| Zenith Capital Corp. | -8.94 Million USD | 62.458% |
| Agentix Corp. | -1.37 Million USD | -144.751% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 33.444% |
| Biomind Labs Inc. | -1 Million USD | -232.545% |
| ContraFect Corporation | -56.88 Million USD | 94.098% |
| CSL Limited | 3.7 Billion USD | 100.091% |
| CytoDyn Inc. | -18.05 Million USD | 81.408% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -80.082% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -761.818% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 93.952% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -708.076% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -118.573% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -388.738% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 104.102% |
| SQZ Biotechnologies Company | -75.82 Million USD | 95.572% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -69.012% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 95.323% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -17.782% |
| Mesoblast Limited | -84.14 Million USD | 96.01% |
| Marizyme, Inc. | -34.08 Million USD | 90.15% |
| Genus plc | 6.4 Million USD | 152.459% |
| Pharming Group N.V. | -4.87 Million USD | 31.195% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 59.792% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -139.473% |
| IMV Inc. | -38.67 Million USD | 91.318% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -22.05% |
| MultiCell Technologies, Inc. | -722.81 USD | -464390.807% |
| ONE Bio Corp. | 13.68 Million USD | 124.54% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 94.309% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 194.841% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -15.722% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 49.498% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -11109.221% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 78.844% |
| Alpha Cognition Inc. | -9.7 Million USD | 65.408% |
| Enzolytics Inc. | -2.14 Million USD | -56.245% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.21% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -221.589% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -15.001% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.193% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 168.312% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -1182.787% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -36.739% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -1857.551% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -67.471% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 134.461% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 26.288% |
| Adynxx, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | 10.384% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -241.179% |
| EV Biologics, Inc. | -483.06 Thousand USD | -595.022% |
| Q BioMed Inc. | -3.44 Million USD | 2.561% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -167.308% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 93.893% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.77 Million USD | 56.84% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -73.723% |
| HST Global, Inc. | -140.9 Thousand USD | -2282.696% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -151.408% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -198.459% |
| Halberd Corporation | -75.05 Thousand USD | -4373.532% |
| Resverlogix Corp. | -12.74 Million USD | 73.665% |
| Cell Source, Inc. | -4.32 Million USD | 22.379% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -112.58% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 6.69 Million USD | 150.164% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -19172.062% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -2.46 Million USD | -36.105% |
| Kadimastem Ltd | -3.04 Million USD | -10.431% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 20.787% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -1749.952% |
| LadRx Corporation | -3.82 Million USD | 12.194% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -388.738% |
| Affymax, Inc. | -15.04 Million USD | 77.686% |
| Itoco Inc. | -919.14 Thousand USD | -265.275% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -200.034% |
| Mobile Lads Corp. | -554.55 Thousand USD | -505.425% |
| International Stem Cell Corporation | -663 Thousand USD | -406.393% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Bioxytran, Inc. | -3.82 Million USD | 12.114% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -13238.84% |
| Qrons Inc. | -643.67 Thousand USD | -421.595% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -494.519% |
| SYBLEU INC | -149.18 Thousand USD | -2150.56% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -50.564% |
| Rebus Holdings, Inc. | -664 Thousand USD | -405.63% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -84.846% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -6278.013% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -16406.323% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 90.742% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -107.502% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -356.269% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -7.92% |
| Neutra Corp. | -229.48 Thousand USD | -1363.003% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 80.858% |
| PureTech Health plc | -146.19 Million USD | 97.704% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 84.378% |
| IXICO plc | -1.43 Million USD | -133.639% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 64.626% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 97.244% |
| CSL Limited | 3.81 Billion USD | 100.088% |
| Cellectis S.A. | -108.85 Million USD | 96.916% |